Guest Post: More on the legitimacy of assumed consent

/ By / Copyright

Readers may recall the strange email that the news website Medianama received from Thomson Reuters recently. (We wrote about it here). In short, Thomson Reuters had sent Medianama an email stating that unless they explicitly denied them permission, they would assume permission to use and reproduce Medianama’s content. While Thomson Reuters has since sent in an apology to Medianama, the question of the validity of such an email prompted many of our readers to send in some very pertinent comments. […]

Guest Post: More on the legitimacy of assumed consent Read More »

Call for Papers: The Indian Journal of Law and Technology 2014-15.

/ By / Others

The  readers may be interested in knowing that the Indian Journal of Law and Technology is inviting submissions for its eleventh volume. The details are provided below. The Indian Journal of Law and Technology is pleased to invite submissions for its 11th Volume due to be published in 2015  The Journal The Indian Journal of Law and Technology (IJLT) is a student-run open-access law journal published annually by the National Law School of India University, Bangalore, India (NLSIU). It is

Call for Papers: The Indian Journal of Law and Technology 2014-15. Read More »

Global Congress on Intellectual Property and the Public Interest, 2015

/ By / Others

SpicyIP is pleased to announce that the Centre for Internet and Society (CIS) will be hosting the fourth edition of the Global Congress on Intellectual Property and the Public Interest at New Delhi, India. The event will be tentatively scheduled in the first two weeks of December, 2015. The exact dates will be announced once the WIPO releases its annual calendar and list of events to avoid clashing of events. The Global Congress on Intellectual Property and the Public Interest

Global Congress on Intellectual Property and the Public Interest, 2015 Read More »

Stalling scientific progress with chilly copyright censure

/ By / Copyright

[Apologies in advance for the long post. Though its been over a month since this development, I’ve seen it discussed very little anywhere else and thought it better to include as much as I could on it. If you too find this development troubling, please do share it on with your networks to help spread word of it]  Fact scenario:  Diego A. Gómez Hoyos is a 26 year old student, currently in Costa Rica studying for a master’s degree in

Stalling scientific progress with chilly copyright censure Read More »

SpicyIP Weekly Review (August 18 – 24, 2014)

/ By / Others

In case you missed us the past week, here’s a roundup of all the stories that we carried on the blog over the past week. We started the week off with Anubha’s post on the case of Dandi Salt v. Union of India. She analyses this decision of J. Vibhu Bakhru of the Delhi High Court which concludes that the Registrar of Copyrights does not have the power to adjudicate upon the merits of an application preferred by the Copyright

SpicyIP Weekly Review (August 18 – 24, 2014) Read More »

PLCS 2014- Pharma Legal and Compliance Summit 2014

/ By / Event, Sponsored

SpicyIP is pleased to announce the 3rd Annual Pharma Legal & Compliance Summit 2014. The details are as follows: The Pharma Legal & Compliance Summit was launched in 2012 and ever since has successfully come up with 2 editions. We now present The 3rd Annual Edition which is to be scheduled for 19th September 2014, Mumbai. The summit brings to you a day of brainstorming sessions with the leaders and veterans of the industry. Addressing the complications and concerns to

PLCS 2014- Pharma Legal and Compliance Summit 2014 Read More »

MAELS 2014- 3rd Annual Media, Advertising and Entertainment Legal Summit

/ By / Event, Sponsored

SpicyIP is pleased to announce the 3rd Annual Media, Advertising and Entertainment Legal Summit (MAELS 2014). Details are as follows: An aggressive industry research that Lex Witness conducted within the various stakeholders of the industry reflects a lot of ambiguity in the understanding of the current legal & regulatory regime. The 3rd Annual Edition of Media, Advertising &Entertainment Legal Summit 2014 promises to brainstorm on the challenges faced by the Media, Advertising & Entertainment Industry and we shall together look

MAELS 2014- 3rd Annual Media, Advertising and Entertainment Legal Summit Read More »

SpicyIP Tidbit: All your content belongs to us (unless you opt out)!

/ By / Copyright

[Update to this post has been made below – regarding a provision in the Copyright Act which may in fact allow this!] Do you know of a copyright provision anywhere in the world that would allow your content (that you created), become an unrelated party’s property unless you sent them an email stating that you’d like to keep your copyright over it? If the letter that our friends over at Medianama received recently are of any indication, Thomson Reuters seems

SpicyIP Tidbit: All your content belongs to us (unless you opt out)! Read More »

Access to Medicines for Hepatitis C: Part II – Evaluating the Arsenal

/ By / Drug Regulation, Patent

Gilead’s 300$ a bottle (900$/12 weeks) announcement for blockbuster anti Hepatitis C drug ‘Sovaldi’ comes at a time when Gilead is under tremendous pressure internationally from both governments and civil society organisations to decrease their exorbitant pricing (see here, here and here). In Part I of this post I described developments in India in relation to the drug. In this post I look at the larger picture and situate Gilead’s pricing decisions in the context of targeted advocacy as well as the existence of and willingness

Access to Medicines for Hepatitis C: Part II – Evaluating the Arsenal Read More »

Access to Medicines for Hepatitis C: Part I – Gilead Annouces 300$ price for Sovaldi

/ By / Drug Regulation, Patent

After a huge outcry over its exorbitant price, Gilead Science is offering its Hepatitis C (HCV) blockbuster drug ‘Sovaldi’ at a significant discount in India. As the Times of India reports, Sovaldi will now be available at a price of 900$/12 weeks which is roughly 1% of the US price (a whopping 84,000$/12 weeks). This announcement follows earlier accords with Egypt and Doctors Without Borders to sell the drug at this discounted price to low income countries. With an estimated

Access to Medicines for Hepatitis C: Part I – Gilead Annouces 300$ price for Sovaldi Read More »

Scroll to Top